The FDA Admits The Existence Of 'Unpleasant Actions' From The Neuralink Animal Testing Facility

Neuralink conducts unpleasant practices at animal testing facilities (photo: X @neuralink)

JAKARTA - The Food and Drug Administration (FDA) found practices that were considered 'unpleasant' in the veterinary testing laboratory owned by Neuralink, a neurotechnology company owned by Elon Musk.

According to a Reuters report, the FDA initially found problems at the Neuralink animal testing facility in California in June last year. The matter came to light within weeks of Neuralink obtaining an implantation study permit for humans.

Congress filed a complaint regarding the matter on November 29 and the FDA responded to concerns from one of its members, Earl Blumenauer. According to the FDA, problems with the Neuralink animal testing facility do exist, but not severe enough.

In fact, the FDA says that the issues reported by Congress do not require special action from them. For the FDA, the problems found in Neuralink require only voluntary improvement from the brain chip maker.

"Although the company did receive a ticket regarding the documentation of its animal research, the FDA examination found no evidence of any violations that could jeopardize the security of the device," the FDA said in a statement.

Although the FDA has repeatedly mentioned the existence of 'unpleasant' conditions at the Neuralink animal research center, it is not explained what conditions have raised Blumenauer's concerns. The FDA only revealed that this issue relates to animal handling for testing.

Neuralink is considered to have carried out practices that go beyond regulations. In February, it was revealed that there was a problem with quality control and record storage in the Neuralink lab. There is a possibility of this issue being discussed by the FDA and Congress.